# Sintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therapy for uBTC.

> clinical trial · VERIFIED · 2026-06-17

Status: ACTIVE_NOT_RECRUITING · Sponsor: Tianjin Medical University Cancer Institute and Hospital · Condition: Biliary Tract Cancers (BTC)

- Company: Tianjin Medical University Cancer Institute and Hospital
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07654530

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.